Dnmt3b Peptide
€100.00
In stock
SKU
350465
Protein Family: Enzymes
Pathway and Disease: Amino Acid Metabolism, Replication and Repair
Alternate Names: DNA (cytosine-5)-methyltransferase 3B; Dnmt3b; DNA methyltransferase HsaIIIB; DNA MTase HsaIIIB; M.HsaIIIB
Accession No.: Q9UBC3, NP_008823
Description:
Dnmt3B is required for genome wide de novo methylation and is essential for development. Defects in Dnmt3B are a cause of immunodeficiency-centromeric instability-facial abnomalies syndrome (ICF), characterized biochemically by hypomethylation of CpG sites in heterochromatin.
Format:
Each vial contains 0.1 mg of lyophilized peptide. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. Use at 5.6 ug/ml for a 100X excess over antibody for maximum blocking effect.
MW: 1675.8 g/mol
Sequence:
The synthetic peptide used to raise the antibody Cat. No. 200103 is selected from a sequence within the N-term region of human Dnmt3b. For blocking experiments, a 10 to 100 fold molar excess to antibody is recommended.
Composition:
C65H106N22O26S2
Purity:
> 80% by HPLC
Solubility:
Distilled water for a solution up to 2 mg/ml, otherwise we recommend using acetonitrile.
Storage:
Store at -20°C. The product is hygroscopic and must be protected from light. Product is guaranteed one year from the date of shipment. Following reconstitution, store at -20°C.
Pathway and Disease: Amino Acid Metabolism, Replication and Repair
Alternate Names: DNA (cytosine-5)-methyltransferase 3B; Dnmt3b; DNA methyltransferase HsaIIIB; DNA MTase HsaIIIB; M.HsaIIIB
Accession No.: Q9UBC3, NP_008823
Description:
Dnmt3B is required for genome wide de novo methylation and is essential for development. Defects in Dnmt3B are a cause of immunodeficiency-centromeric instability-facial abnomalies syndrome (ICF), characterized biochemically by hypomethylation of CpG sites in heterochromatin.
Format:
Each vial contains 0.1 mg of lyophilized peptide. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. Use at 5.6 ug/ml for a 100X excess over antibody for maximum blocking effect.
MW: 1675.8 g/mol
Sequence:
The synthetic peptide used to raise the antibody Cat. No. 200103 is selected from a sequence within the N-term region of human Dnmt3b. For blocking experiments, a 10 to 100 fold molar excess to antibody is recommended.
Composition:
C65H106N22O26S2
Purity:
> 80% by HPLC
Solubility:
Distilled water for a solution up to 2 mg/ml, otherwise we recommend using acetonitrile.
Storage:
Store at -20°C. The product is hygroscopic and must be protected from light. Product is guaranteed one year from the date of shipment. Following reconstitution, store at -20°C.
| Is Featured? | No |
|---|
Write Your Own Review